MGRX MANGOCEUTICALS, INC.
Services-Misc Health & Allied Services, NEC · Nasdaq · SEC CIK 1938046 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-35.6%
TTM net income YoY44.3%
TTM EPS YoY80.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin52.9%
Operating margin-2,608.1%
Net margin-3,673.7%
FCF margin—
EBITDA margin-2,607.7%
Returns
ROE-82.3%
ROA-69.8%
ROIC (approx.)-48.2%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets9.4%
Debt / equity0.00x
Current ratio1.28x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.34x
Accruals ratio-45.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $69,503 | $68,757 | $67,864 | $94,360 | $84,246 | $168,109 | $109,306 | $105,247 |
| Cost of revenue | $8,813 | $10,437 | $8,218 | $8,511 | $2,359 | $18,815 | $24,737 | $21,331 |
| Gross profit | $38,397 | $44,215 | $29,001 | $47,475 | $50,899 | $89,948 | $62,064 | $80,103 |
| SG&A expense | $428,955 | $256,095 | $1.05M | $657,190 | $311,379 | $1.25M | $1.54M | $854,054 |
| Operating income | -$3.31M | -$1.03M | -$3.13M | -$367,739 | -$7.26M | -$5.27M | -$4.58M | -$1.68M |
| Interest expense | $1,099 | — | — | $19,663 | $75,850 | $21,700 | -$13,700 | — |
| Pretax income | -$3.55M | -$1.31M | -$3.40M | -$2.77M | -$7.62M | -$5.42M | -$4.84M | -$1.95M |
| Net income | -$3.55M | -$1.31M | -$3.40M | -$2.77M | -$7.62M | -$5.42M | -$4.84M | -$1.95M |
| EBITDA | -$3.31M | -$1.03M | -$3.13M | -$367,485 | -$7.26M | -$5.27M | -$4.58M | -$1.67M |
| EPS (basic) | -0.19 | -0.09 | -0.22 | — | -0.69 | -0.57 | -1.12 | — |
| EPS (diluted) | -0.19 | -0.09 | -0.22 | — | -0.69 | -0.57 | -1.12 | — |
| Weighted avg. shares (diluted) | 20.42M | 17.12M | 16.48M | — | 11.52M | 9.98M | 4.59M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $659,258 | $228,688 | $174,562 | $1.49M | $481,281 | $101,019 | $76,496 | $58,653 |
| Current assets | $1.49M | $245,687 | $212,472 | $1.55M | $598,223 | $117,961 | $176,652 | $75,595 |
| PP&E, net | $1,037 | $1,292 | $1,544 | $1,794 | $2,049 | $2,304 | $2,556 | $2,806 |
| Intangibles | $13.35M | $13.65M | $13.94M | $14.23M | $15.92M | $20.69M | $21.53M | $15.23M |
| Total assets | $15.11M | $14.17M | $14.45M | $16.09M | $16.53M | $20.84M | $21.75M | $15.37M |
| Current liabilities | $1.16M | $1.40M | $737,606 | $890,568 | $804,275 | $1.60M | $1.50M | $1.43M |
| Total liabilities | $1.41M | $1.65M | $974,571 | $890,568 | $804,275 | $1.60M | $1.50M | $1.43M |
| Shareholders' equity | $11.08M | $12.53M | $13.48M | $15.20M | $15.73M | $19.24M | $20.25M | $13.95M |
| Shares outstanding | 21.57M | 18.02M | 16.97M | 15.89M | 13.88M | 10.64M | 7.14M | 3.25M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.15M | -$260,506 | -$1.31M | -$1.08M | -$1.24M | -$1.26M | -$2.27M | -$1.13M |
| Investing cash flow | — | — | — | — | — | — | — | $0 |
| Financing cash flow | $1.58M | — | — | $2.08M | $1.62M | $1.28M | $2.29M | $1.12M |
| Depreciation & amortization | $255 | $252 | $250 | $254 | $256 | $252 | $250 | $7,935 |
| Stock-based compensation | $1.05M | $12,417 | $1.09M | -$33,471 | $1.10M | $50,979 | $50,979 | $50,979 |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.